RHUDEX
DEAD

Serial Number

88245830

Owner

Medigene AG

Attorney

David A. Bell

Filing Date

Dec 31, 2018

Add to watchlist:

No watchlists yet
View on USPTO

RHUDEX Trademark

Serial Number: 88245830 • Registration: 5812401

RHUDEX is a trademark filed by Medigene AG on December 31, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Medigene AG

Lochhamer Str. 11
Planegg-Martinsried 82152 , DE

Entity Type: 99

Trademark Details

Filing Date

December 31, 2018

Registration Date

July 23, 2019

Published for Opposition

May 7, 2019

Cancellation Date

February 6, 2026

Goods & Services

Biotechnology services, namely, the development of T-cell receptor pharmaceutical products and technologies for the treatment of cancer, rheumatoid arthritis, inflammatory and auto-immune diseases; scientific and medical research and development of new technology for others in the field of biotechnology and genomics, pharmaceutical drug development services, and pharmaceutical product development; genetic engineering services, licensing intellectual property, namely, trademarks and patents in the field of biotechnology

Apparatus and instruments for diagnostic and therapeutic research, namely, instruments for measuring tissue damage or movement in limbs or organs; display apparatus, namely, multi-well plates and arrays for medical or clinical diagnosis and analysis; surgical and medical apparatus and instruments, namely, injectors and syringes

Antibodies, proteins, T cell proteins and peptides for medical use, monoclonal antibodies for clinical or medical use, pharmaceutical and biochemical substances and preparations, namely, small molecules, and CD8O antagonists for the treatment of cancer, rheumatoid arthritis and auto-immune diseases; in vivo immunotherapeutic, immunoprophylactic and immunodiagnostic agents, preparations and substances for clinical or medical use; vaccines; protein conjugates; diagnostic and analytical preparations for medical and veterinary use, namely, products to diagnose and analyze tissue damage caused by inflammation due to auto-immune diseases; enzymes and enzyme preparations for clinical or medical use and the treatment of cancer, rheumatoid arthritis and auto-immune diseases; chemical products for use in medical science, namely, T-cell receptors, small molecule and protein therapeutics; pre-filled vials containing pharmaceuticals and bioceuticals, namely, small molecules and protein therapeutics involving T-cell receptors for the treatment of cancer, rheumatoid arthritis and auto-immune diseases

Filing History

CANCELLED SEC. 8 (6-YR)
Feb 6, 2026 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Jul 23, 2024 REM1
REGISTERED-PRINCIPAL REGISTER
Jul 23, 2019 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 7, 2019 NPUB
PUBLISHED FOR OPPOSITION
May 7, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 17, 2019 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 25, 2019 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 25, 2019 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 22, 2019 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 22, 2019 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 22, 2019 CNEA
ASSIGNED TO EXAMINER
Mar 20, 2019 DOCK
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Mar 20, 2019 AMPX
ASSIGNED TO LIE
Mar 11, 2019 ALIE
TEAS VOLUNTARY AMENDMENT RECEIVED
Mar 8, 2019 PARI
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 22, 2019 NWOS
NEW APPLICATION ENTERED
Jan 3, 2019 NWAP